Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]
Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals. We have developed a biomarker-based assay for predicting the cardiotoxicity of compounds based on changes in metabolism. This assay is an attractive new model that can identify both structural and functional cardiotoxic compounds that could be used in conjunction with CiPA and other endpoints.
Download the poster:
[pardot-form id=”2372″ title=”SOT 2018: Development of an In Vitro Assay to Predict Cardiotoxicity Potential”]